Table II.
The intestinal tumor growth, calcium level and blood leukocyte count in mice bearing HT-29 tumors.
| 5-FU intraperitoneally | 5-FU intravenously | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| Group | Tumor weight on day 39 (g) | TGI (%) | H (%) | Leukocytes (thousands/μl) | N | Tumor weight on day 53 (g) | TGI (%) | H (%) | Calcium (mmol/l) | N |
| Control | 0.305±0.140 | 5.5±1.3 | 6 | 0.808±0.24 | -- | 2.50±0.07 | 6 | |||
| PRI-2191 | nt. | nt. | nt. | 0.657±0.20 | 20 | 2.61±0.07 | 5 | |||
| PRI-2205 | 0.291±0.199 | 5 | 5.7±0.6 | 7 | 0.663±0.38 | 35 | 2.42±0.08 | 5 | ||
| 5-FU | 0.138±0.072 | 55 | 4.2±1.3 | 6 | 0.527±0.33 | 37 | 2.48±0.03 | 7 | ||
| 5-FU + PRI-2191 | nt. | nt. | nt. | 0.268±0.09a | 66 | 49 | 2.55±0.04 | |||
| 5-FU + PRI-2205 | 0.097±0.062a | 68 | 57 | 3.5±1.0 | 7 | 0.259±0.08a | 68 | 59 | 2.49±0.02 | 6 |
(%) H, the expected inhibition used to estimate the effect of the combination of two compounds was evaluated using the formula (%) H = 100 − [(100 − E for cytostatic) × (100 − E for calcitriol analog)/100], where E was tumor growth inhibition (TGI). N, no. of mice/group; nt., not tested.
a
P<0.05 as compared to control and PRI-2205, ANOVA followed by Tukey HSD test for unequal N.